#24. Christopher T. Cox Buys $3.5M of MEDICINES CO /DE latest buy: 12/08/2016
During the last six months, Cox bet big on MDCO:
Christopher T. Cox
EVP & Chief Corp. Dev. Officer
Medicines is a biopharmaceutical company, engaged in acute/intensive care hospitals worldwide. Co. markets Angiomax® (bivalirudin), Cleviprex® (clevidipine) injectable emulsion, Ionsys® (fentanyl iontophoretic transdermal system), Kengreal® (cangrelor), Minocin (minocycline) for injection, and Orbactiv® (oritavancin). Co. also has a pipeline of acute and intensive care hospital products in development, including ABP-700, ALN-PCSsc, Carbavance® and MDCO-216. Co. has the right to develop, manufacture and commercialize ALN-PCSsc under its collaboration agreement. In addition, Co. sells a ready-to-use formulation of Argatroban and has a portfolio of ten generic drugs.
MDCO — Key Stats (updated Friday, February 17, 10:33 AM)
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.